<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204629</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ESOM-103</org_study_id>
    <nct_id>NCT04204629</nct_id>
  </id_info>
  <brief_title>Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics and Pharmacodynamics of HIP1601 40 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective - To evaluate food effect on the pharmacokinetics and the pharmacodynamics
      (PD) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition.

      Secondary objectives

      - To evaluate the safety of single oral dose of HIP1601 in healthy subjects under fed or
      fasting condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Maximum observed concentration after dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration versus time Curve(AUC)last</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Area under the plasma concentration versus time curve from dosing to the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Integrated gastric acidity for 24-hour</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Percent decrease from baseline in integrated gastric acidity for 24-hour interval after dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Time of Cmax over the time span specified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Area under the plasma concentration versus time curve from the time of dosing to time extrapolated to infinitely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance/F</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Apparent total body clearance after extravascular administration, calculated as Dose/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Apparent volume of distribution after extravascular administration, calculated as Dose/(λzㆍAUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of time intra-gastric pH 4.0 or higher</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Percent of time with intra-gastric pH greater than 4.0 for 24-hour interval after dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median pH</measure>
    <time_frame>Blood sampling during 24 hours after administration</time_frame>
    <description>Median intra-gastric pH for 24-hour interval after dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP1601 40mg</intervention_name>
    <description>Single dosing of HIP1601 40mg, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>HIP1601</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female healthy volunteers in the age between 19 and 50 years old.

          -  Body mass index (BMI) in the range of 19 to 28 kg/m2 and weight 55.0kg to 90.0kg.

          -  Helicobacter pylori (H. Pylori) negative.

          -  After fully hearing and understanding the details of this clinical trial, Subjects who
             have willingness to sign of informed consent before the screening.

          -  Subject who are eligible from physical examination, clinical laboratory test by
             investigators judgment.

        Exclusion Criteria:

          -  Gastrointestinal disorders (gastrointestinal ulcers, gastritis, stomach cramps,
             gastro-esophageal reflux disease, Crohn's disease or chronic pancreatitis) or
             gastrointestinal surgery (except for simple cecal or hernia surgery) which may affect
             the safety and pharmacokinetic evaluation of test drug.

          -  Subjects who have a history of hypersensitivity or clinically significant
             hypersensitivity to esomeprazole or the same component or other drugs (aspirin,
             antibiotics, etc.).

          -  Blood serum aspartate aminotransferase and alanine aminotransferase exceed 1.5 times
             the upper limit of normal range from screening laboratory results before
             randomization.

          -  Subject who continues to drink (21 units / week, 1 unit = 10 g of pure alcohol) within
             a month before the screening visit or who cannot abstain during the hospital stay.

          -  Heavy smoker (&gt;10 cigarettes/day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jina Jung Jung</last_name>
    <phone>82-2-410-9038</phone>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Biomedical Research Institute</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

